一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Apoptosis >>article
Apoptosis

Apoptosis

IF: 6.1
Download PDF

Exploratory study on the efficacy of bortezomib combining mitoxantrone or CD22-CAR T therapy targeting CD19-negative relapse after CD19-CAR T cell therapy with a simpler cell-line-based model.

Published:27 May 2023 DOI: 10.1007/s10495-023-01853-1 PMID: 37243774
Diandian Ba, Hongzhe Li, Rongrong Liu, Ping Zhang, Yongmin Tang

Abstract

Target-negative relapse after CD19 chimeric antigen receptor engineered (CAR) T cell therapy for patients with B lineage acute lymphoblastic leukemia (B-ALL) presents limited treatment options with dismal outcomes. Although CD22-CAR T cells mediate similarly potent antineoplastic effects in patients with CD19dim or even CD19-negative relapse following CD19-directed immunotherapy, a high rate of relapse associated with diminished CD22 cell surface expression has also been observed. Therefore, it is unclear whether any other therapeutic options are available. Mitoxantrone has shown significant antineoplastic activity in patients with relapsed or refractory leukemia over the past decades, and in some cases, the addition of bortezomib to conventional chemotherapeutic agents has demonstrated improved response rates. However, whether this mitoxantrone and bortezomib combination therapy is effective for those patients who have relapsed B-ALL after receiving CD19-CAR T cell therapy remains to be elucidated. In this study, we established a cellular model system using a CD19-positive B-ALL cell line Nalm-6 to investigate the treatment options for CD19-negative relapsed B-ALL after CD19-CAR T cell therapy. In addition to CD22-CAR T therapy, we observed that the combination of bortezomib and mitoxantrone exhibited effective anti-leukemia activity in the CD19-negative Nalm-6 cell line by downregulating p-AKT and p-mTOR. These results suggest that this combination therapy is a possible option for target-negative refractory leukemia cells after CAR-T cell treatment.

Substances (4)

Materials
Procduct Name CAS Molecular Formula Supplier Price
Mitoxantrone 65271-80-9 C22H28N4O6 259 suppliers $11.00-$1732.50
Mitoxantrone 65271-80-9 C22H28N4O6 259 suppliers $11.00-$1732.50
Mitoxantrone 65271-80-9 C22H28N4O6 259 suppliers $11.00-$1732.50
Mitoxantrone 65271-80-9 C22H28N4O6 259 suppliers $11.00-$1732.50

Similar articles

IF:6.1

Systemic tumor regression with synergy therapy: radiotherapy and CAR-T

Cell Death Discovery Ma, Xingyu,etc Published: 22 November 2024
IF:40.8

Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors

Signal Transduction and Targeted Therapy Zhu, Chaojie,etc Published: 22 November 2024
IF:10

Hybrid Cell Membrane‐Coated Nanoparticles for Synergizing Sonodynamic Therapy and Immunotherapy against Triple‐Negative Breast Cancer

Advanced Healthcare Materials Jiali Gong, Danling Cheng,etc Published: 21 November 2024
昭觉县| 乐昌市| 本溪市| 安图县| 鸡泽县| 微山县| 蒲城县| 珲春市| 射洪县| 天津市| 绵阳市| 扶风县| 梅河口市| 凯里市| 栾城县| 五大连池市| 长垣县| 华容县| 威海市| 修武县| 万载县| 克什克腾旗| 济源市| 西丰县| 新源县| 沂水县| 绥芬河市| 汶川县| 汉川市| 石林| 香河县| 龙陵县| 怀宁县| 自治县| 龙江县| 吴忠市| 晋江市| 永靖县| 海城市| 德安县| 什邡市|